London-based AI life sciences startup Basecamp Research raised a $140M Series C led by S32, with participation from Anthropic, taking its total funding to $225M
Basecamp says it will use the funding to train a new generation of its AI models. — A UK life sciences startup using AI …
Tech.euJohn Reynolds
Context & Ripple Effects
Basecamp’s 2024 Series B brought its disclosed funding to $85M and was tied to its claim that BaseFold outperformed AlphaFold 2 on protein prediction. The new financing gives the company substantially more resources to develop its next model generation.
The round lands in an increasingly funded European biology-model field: Paris-based Bioptimus raised $41M for a biology foundation model, while Latent Labs emerged with $50M to make biology programmable. Anthropic’s participation links a frontier AI company to Basecamp’s life-sciences model effort.
First-order effects
Basecamp can direct the new capital toward training its next-generation AI models, extending the model-development work it funded with its 2024 Series B.
S32 and participating investor Anthropic gain exposure to Basecamp’s effort to apply AI models to life sciences.
Second-order effects
Bioptimus and Latent Labs face a better-capitalized peer in the competition to build biology foundation models, raising the financing and technical-execution benchmark for their own programs.
Basecamp’s $225M total funding makes the company a more consequential buyer of the data, research capacity, and computing needed to train life-sciences models.
Third-order effects
If comparable rounds continue, AI biology may consolidate around a smaller group of companies able to finance both large-scale model training and the research programs needed to validate outputs.
The field’s competitive advantage is likely to rest increasingly on the combination of proprietary biological data and capital to turn models into therapeutic programs, rather than model claims alone.
The trend: AI life-sciences startups are raising larger rounds to pair foundation-model development with the data and validation infrastructure required for drug-development work.
Congratulations to Basecamp Research, an NVentures portfolio company, on their $140M Series C announced today. Particularly interested in this one — in a past life, I spent time as a scientist mining the natural world for novel genes and metabolic pathways. @Basecamp_Res trains f…
We met @glen_gowers and Oliver Vance in 2021 through @viswacolluru of @enveda. That founder-to-founder path means everything to us. It signals that we've earned enough trust to be introduced to ambitious founders and ideas long before the answers are obvious.
AI is giving us new ways to read biology at a scale we've never had before. @BasecampResearch is building from one of the richest sources available: evolution itself. Their data now spans 30+ countries and powers EDEN, trained on 9.7T nucleotides to help design new medicines. Tod…
@SebJohnsonUK @glen_gowers 800M post-money and the asset is the genomic dataset, Micro1 yesterday, Basecamp today, the labs are buying into the data though
A UK startup has just raised $140m to design new medicines with AI. The London startup is founded by @glen_gowers and Oliver Vince, and just announced their $140m Series C led by S32, with NVIDIA and Anthropic joining as new investors as well. Basecamp Research is teaching AI to …
We've invested in @Basecamp_Res as part of its $140m round. Basecamp has built a database of genetic information from 1m+ unstudied organisms, using it to design new medicines, including cancer and autoimmune therapies. The potential to transform medicine discovery is huge.